阿美替尼(HS-10296)在晚期EGFR T790M阳性非小细胞肺癌患者中的疗效:APOLLO注册试验国家药品监督管理局批准后更新结果
APOLLO注册2期试验纳入244例经第一/二代EGFR TKI治疗后进展、EGFR T790M阳性的局部晚期或转移性非小细胞肺癌患者,口服阿美替尼110 mg每日一次。独立中心评估客观缓解率68.9%,中位无进展生存期12.4个月,≥3级治疗相关不良事件发生率16.4%。
要点
- 阿美替尼110 mg每日一次在EGFR T790M阳性晚期NSCLC中客观缓解率68.9%。
- 中位无进展生存期12.4个月,中位缓解持续时间15.1个月。
- ≥3级治疗相关不良事件发生率16.4%,最常见为血肌酸磷酸激酶升高(7%)。
核心结论
- 阿美替尼是有效的、耐受良好的第三代EGFR TKI,适用于第一/二代EGFR TKI治疗后进展的EGFR T790M阳性晚期NSCLC患者。
- 基于这些结果,阿美替尼在中华人民共和国获批用于EGFR T790M阳性NSCLC患者。
研究设计与样本
- 注册2期试验(NCT02981108),纳入第一/二代EGFR TKI治疗后进展出现EGFR T790M突变的局部晚期或转移性NSCLC患者。
- 阿美替尼110 mg口服每日一次;主要终点为独立中心评估的客观缓解率。
- 共纳入244例EGFR T790M阳性NSCLC患者。
主要发现
- 独立中心评估的客观缓解率为68.9%(95%CI:62.6-74.6)。
- 疾病控制率为93.4%(95%CI:89.6-96.2)。
- 中位缓解持续时间为15.1个月(95%CI:12.5-16.6)。
- 中位无进展生存期为12.4个月(95%CI:9.7-15.0)。
- 23例可评估中枢神经系统转移患者中,中枢神经系统客观缓解率为60.9%(95%CI:38.5-80.3),中枢神经系统疾病控制率为91.3%(95%CI:72.0-98.9);中位中枢神经系统缓解持续时间为12.5个月(95%CI:5.6-未达到)。
关键数值与推荐
- 客观缓解率68.9%(95%CI:62.6-74.6),疾病控制率93.4%(95%CI:89.6-96.2)。
- 中位缓解持续时间15.1个月(95%CI:12.5-16.6),中位无进展生存期12.4个月(95%CI:9.7-15.0)。
- 中枢神经系统客观缓解率60.9%(95%CI:38.5-80.3),中枢神经系统疾病控制率91.3%(95%CI:72.0-98.9)。
- ≥3级治疗相关不良事件发生率16.4%,最常见为血肌酸磷酸激酶升高(7%)和丙氨酸氨基转移酶升高(1.2%)。
- 阿美替尼相对剂量密度为99.2%。
临床怎么用
- 阿美替尼110 mg口服每日一次用于第一/二代EGFR TKI治疗后进展的EGFR T790M阳性晚期NSCLC患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Aumolertinib (formerly almonertinib; HS-10296) is a novel third-generation EGFR tyrosine kinase inhibitor (TKI) with revealed activity against EGFR-sensitizing mutations and EGFR T790M mutation. METHODS: Patients with locally advanced or metastatic NSCLC who developed an EGFR T790M mutation after progression on first- or second-generation EGFR TKI therapy were enrolled in this registrational phase 2 trial of aumolertinib at 110 mg orally once daily (NCT02981108). The primary end point was objective response rate (ORR) by independent central review. RESULTS: A total of 244 patients with EGFR T790M-positive NSCLC were enrolled. The ORR by independent central review was 68.9% (95% confidence interval [CI]: 62.6-74.6). The disease control rate was 93.4% (95% CI: 89.6-96.2). The median duration of response was 15.1 months (95% CI: 12.5-16.6). The median progression-free survival was 12.4 months (95% CI: 9.7-15.0). Among 23 patients with assessable central nervous system (CNS) metastases, the CNS-ORR and CNS-disease control rate were 60.9% (95% CI: 38.5-80.3) and 91.3% (95% CI: 72.0-98.9), respectively. The median CNS-duration of response was 12.5 months (95% CI: 5.6-not reached). Treatment-related adverse events of more than or equal to grade 3 occurred in 16.4% of the patients, with the most common being increased blood creatine phosphokinase level (7%) and increased alanine aminotransferase level (1.2%). The relative dose density of aumolertinib was 99.2% in this study. CONCLUSIONS: Aumolertinib is an effective and well-tolerated third-generation EGFR TKI for patients with EGFR T790M-positive advanced NSCLC after disease progression on first- and second-generation EGFR TKI therapy. On the basis of these findings, aumolertinib was approved in the People's Republic of China for patients positive for EGFR T790M NSCLC.
引用
- Lu S, Wang Q, Zhang G, et al. Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial. J Thorac Oncol. 2021. PMID: 34801749. doi:10.1016/j.jtho.2021.10.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。